Drug intelligence / Profile preview

5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione

Development stage
Preclinical
Lead developer
Merck KGaA
Modality
Small Molecules
01

Overview

5-quioxalin‑6‑ylmethylene‑thiazolidine‑2,4‑dione is a synthetic small molecule belonging to the quinoxaline and thiazolidinedione chemical classes. It acts as a potent and selective inhibitor of phosphatidylinositol 3‑kinase gamma (PI3Kγ), with an IC50 of approximately 8 nM. Preclinical studies have demonstrated its anti-inflammatory and antirheumatic properties by inhibiting the progression of joint inflammation and damage in both lymphocyte-independent and -dependent mouse models of rheumatoid arthritis. The compound has been explored primarily as an experimental tool compound for research into inflammatory diseases but has not advanced to clinical development or approval[1][2][7].

Other names
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione5-(6-quinoxalinylmethylene)-2,4-thiazolidinedione5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dioneCHEBI:45302PI3Kgamma inhibitor IPI-3Kgamma inhibitor IPI 3Kgamma inhibitor I
02

Targets

PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)

Beyond the preview

Go deeper on 5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call